Mirae Asset Global Investments
AUTL icon

Mirae Asset Global Investments’s Autolus Therapeutics AUTL Stock Holding History

Mirae Asset Global Investments’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.4K Sell
8,971
-1,492
-14% -$2.34K ﹤0.01% 1526
2026
Q1 		$14.4K Buy
10,463
+715
+7% +$1.09K ﹤0.01% 1463
2025
Q4 		$19.4K Buy
9,748
+1,994
+26% +$3.06K ﹤0.01% 1537
2025
Q3 		$12.6K Buy
7,754
+8
+0.1% +$16 ﹤0.01% 1547
2025
Q2 		$17.7K Buy
7,746
+1,956
+34% +$3.23K ﹤0.01% 1414
2025
Q1 		$9.61K Sell
5,790
-865
-13% -$1.76K ﹤0.01% 1473
2024
Q4 		$15K Sell
6,655
-565
-8% -$1.91K ﹤0.01% 1460
2024
Q3 		$26.2K Buy
7,220
+1,265
+21% +$5.04K ﹤0.01% 1396
2024
Q2 		$19.8K Buy
+5,955
New +$25.7K ﹤0.01% 1379

Other funds holding AUTL

MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $39B AUM 18.55% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Mirae Asset Global Investments's AUTL Position: Q2 2026 in Review

Mirae Asset Global Investments reduced its Autolus Therapeutics (AUTL) stake by 14% in Q2 2026, selling an estimated $2.34K and leaving 8,971 shares worth $14.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1526.

Mirae Asset Global Investments first reported a position in AUTL in Q2 2024 and has held it in 9 quarters since. The position peaked at $26.2K in Q3 2024. 83 funds tracked by Wall St. Rank hold AUTL as of Q2 2026.

  • Mirae Asset Global Investments held 8,971 shares of Autolus Therapeutics worth $14.4K as of Q2 2026.
  • Mirae Asset Global Investments sold 1,492 Autolus Therapeutics shares in Q2 2026, an estimated $2.34K.
  • Autolus Therapeutics made up ﹤0.01% of Mirae Asset Global Investments's portfolio in Q2 2026, its #1526 holding.
  • Mirae Asset Global Investments first reported a position in Autolus Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • Mirae Asset Global Investments's Autolus Therapeutics position peaked at $26.2K in Q3 2024.
  • 83 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2026.

Based on Mirae Asset Global Investments's 13F filing for Q2 2026, filed 22 Jul 2026.